Mylan and Biocon make USFDA submission for proposed biosimilar trastuzumab

The submitted BLA includes a comprehensive package of analytical similarity, nonclinical and clinical data that consists of two pharmacokinetic studies and a confirmatory efficacy and safety trial, Biocon stated in a release.